Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab.

Abstract	Previous findings from the positron emission tomography (PET) substudy of the SCarlet RoAD and Marguerite RoAD open-label extension (OLE) showed gantenerumab doses up to 1200 mg every 4 weeks administered subcutaneously resulted in robust beta-amyloid (Aβ) plaque removal over 24 months in people with prodromal-to-moderate Alzheimer's disease (AD). In this 36-month update, we demonstrate continued reduction, with mean (standard error) centiloid values at 36 months of -4.3 (7.5), 0.8 (6.7), and 4.7 (8.0) in the SCarlet RoAD (double-blind pooled placebo and active groups), Marguerite RoAD double-blind placebo, and Marguerite RoAD double-blind active groups respectively, representing a change of -57.0 (10.3), -90.3 (9.0), and -74.9 (10.5) centiloids respectively. These results demonstrate that prolonged gantenerumab treatment, at doses up to 1200 mg, reduces amyloid plaque levels below the amyloid positivity threshold. The ongoing GRADUATE Phase III trials will evaluate potential clinical benefits associated with gantenerumab-induced amyloid-lowering in people with early (prodromal-to-mild) AD.
Authors	G Klein, P Delmar, G A Kerchner, C Hofmann, D Abi-Saab, A Davis, N Voyle, M Baudler, P Fontoura, R Doody
Journal	The journal of prevention of Alzheimer's disease (J Prev Alzheimers Dis) Vol. 8 Issue 1 Pg. 3-6 ( 2021) ISSN: 2426-0266 [Electronic] Switzerland
PMID	33336218 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Amyloid beta-Peptides Antibodies, Monoclonal, Humanized gantenerumab
Topics	Aged Aged, 80 and over Alzheimer Disease (diagnostic imaging, drug therapy) Amyloid beta-Peptides (drug effects, metabolism) Antibodies, Monoclonal, Humanized (administration & dosage, pharmacology) Brain (diagnostic imaging, drug effects, metabolism) Double-Blind Method Female Humans Male Middle Aged Positron-Emission Tomography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!